Coronavirus antibody cocktail shortens recovery time, new data shows

Monoclonal coronavirus antibodies.
(Image credit: iStock.)

New data on Regeneron's coronavirus monoclonal antibody cocktail shows the drug is "moving in the right direction," Stat News reports.

A high dose of the cocktail led viral levels to decrease more quickly in non-hospitalized patients. The drug also appeared to have a bigger effect in COVID-19 patients who had not created high levels of antibodies on their own, shortening their recovery time, even at a lower dose.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.